Coagulation factor V Leiden mutation in sudden fatal pulmonary embolism and in a general northern European population sample

Forensic Science International

Volumn 106, Issue 2, 1999, Pages 71-75

  Kuismanen, K ^a   Savontaus, M L ^b   Kozlov, A ^c   Vuorio, A F ^a   Sajantila, A ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c 123363   (Russian Federation)

Author keywords

Factor V; Forensic pathology; Leiden mutation; Population genetics; Pulmonary embolism; Sudden death; Venous thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; RESTRICTION ENDONUCLEASE;

ACTIVATED PROTEIN C RESISTANCE; ADULT; AGED; ARTICLE; AUTOPSY; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; ESTONIA; EUROPE; FATALITY; FEMALE; FINLAND; GENE FREQUENCY; GENOTYPE; HUMAN; HUMAN TISSUE; LUNG EMBOLISM; MALE; POINT MUTATION; PRIORITY JOURNAL; RUSSIAN FEDERATION;

EID: 0032735168     PISSN: 03790738     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0379-0738(99)00136-X     Document Type: Article

References (11)

1. Dahlbäck B., Carlsson M., Svensson P.J. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc. Natl. Acad. Sci. USA. 90:1993;1004-1008.
2. Svensson P.J., Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. New Engl. J. Med. 330:1994;517-522.
3. Koster T., Rosendaal F.R., de Ronde H., Briët E., Vandenbroucke J.P., Bertina R.M. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet. 342:1993;1503-1506.
4. Bertina R.M., Koeleman B.P.C., Koster T., et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 369:1994;64-67.
5. Greengard J.S., Sun X., Xu X., Fernandez J.A., Griffin J.H., Evatt B. Activated protein C resistance caused by Arg506Gln mutation in factor Va. Lancet. 343:1994;1361-1362.
6. 506 of factor V. Lancet. 343:1994;1535-1536.
7. Rosendaal F.R., Koster T., Vandenbroucke J.P., Reitsma P.H. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood. 85:1995;1504-1508.
8. Rees D.C., Cox M., Clegg J.B. World distribution of factor V Leiden. Lancet. 346:1995;1133-1134.
9. Manten B., Westendorp R.G.J., Koster T., Reitsma P.H., Rosendaal F.R. Risk factor profiles in patients with different clinical manifestations of venous thromboembolism: A focus on the factor V Leiden mutation. Thromb. Haemost. 76:1996;510-513.
10. Martinelli I., Cattaneo M., Panzeri D., Mannucci P.M. Low prevalence of factor V:Q506 in 41 patients with isolated pulmonary embolism. Thromb. Haemost. 77:1997;440-443.
11. Kontula K., Ylikorkala A., Miettinen H., et al. Arg506Gln factor V mutation (factor V Leiden) in patients with ischaemic cerebrovascular disease and survivors of myocardial infarction. Thromb. Haemost. 73:1995;558-560.